Clinical Trials Logo
  1. Home
  2. Primary Ovarian Insufficiency
  3. NCT05410093

Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency

Primary Ovarian Insufficiency Clinical Trial

Official title:
Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency

Clinical Trial Summary

Resveratrol is a natural plant antitoxin widely found in grapes, mulberries, and other plants. Resveratrol mediates a variety of pharmacological effects, including antioxidant, immunomodulatory, anti-inflammatory, and anti-apoptotic, and plays a protective and therapeutic role in the development of several ROS-related diseases, including POI/POF.

Clinical Trial Description

The preliminary experiments of the investigators' group examined the gene expression in ovarian granulosa cells of POI patients and normal controls using high-throughput sequencing technology. The investigators found that the expression of NOX complex NCF1, NCF2, NCF4 and CYBB subunit genes were upregulated in ovarian granulosa cells of POI patients compared with normal controls, suggesting that the development of POI may be related to the NOX complex subunit gene and The development of POI may be related to the abnormal expression of genes and proteins of NOX complex subunits. Based on the results of previous experiments and available literature reports, investigators compared ovarian function, embryonic laboratory indices, pregnancy outcome and cellular level NOX/ROS/oxidative stress changes of POI patients in the RES-treated and non-RES-treated groups by collecting blood and ovarian granulosa cell samples to analyze the effects, mechanisms of action and specific RES application in antioxidant therapy for POI NOX subunit targets to provide a reliable scientific basis for the clinical treatment of POI by RES. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05410093
Study type Interventional
Source Affiliated Hospital of Nantong University
Contact wang xia, Master
Phone 15996663288
Email 77109666@qq.com
Status Recruiting
Phase N/A
Start date February 1, 2022
Completion date July 31, 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02871986 - Pubertal Induction in Individuals With Hypogonadism N/A
Recruiting NCT02322060 - In Vitro Activation of Dormant Follicles for Patients With Primary Ovarian Insufficiency
Recruiting NCT06167135 - Polycystic Ovary Syndrome, Mitochondrial Dysfunction, Obesity, Insulin Resistance Infertility (POMODORI) Cohort
Active, not recruiting NCT04675970 - Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy
Completed NCT04943354 - Associations of Combinations of Single-nucleotide Polymorphisms in Women With Premature Ovarian Failure N/A
Recruiting NCT03518918 - Establishing the Diagnosis Standard and Analysis the Risk Factors of POI in Chinese Women
Recruiting NCT05021094 - Clinical Observation on Kuntai Capsule in Treating Early-onset Ovarian Hypofunction Phase 4
Active, not recruiting NCT02795000 - Development a Predictive Nomogram for Primary Ovarian Insufficiency
Suspended NCT03021915 - Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure N/A
Completed NCT01436513 - A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions. Phase 1
Recruiting NCT06117982 - The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency Phase 2
Recruiting NCT02068976 - Observational Epidemiologic Study in Women With Premature Ovarian Failure (POF)
Completed NCT01973075 - Genetic Etiology in Premature Ovarian Insufficiency N/A
Completed NCT03568708 - Primary Ovarian Insufficiency: Phenotype and Optimal Treatment Phase 3
Not yet recruiting NCT02757469 - Oral Contraceptives as Infertility Treatments for Premature Ovarian Failure N/A
Completed NCT02091128 - Pregnancy Chances in Classic Galactosemia N/A
Terminated NCT00650754 - Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility Phase 2/Phase 3
Recruiting NCT03496636 - Autologous Ovarian Tissue Transplantation N/A
Active, not recruiting NCT05737329 - Efficacy, Safety, and Tolerability of Higher Doses Estrogen Therapy in Women With Premature Ovarian Insufficiency Phase 1/Phase 2
Withdrawn NCT02922348 - Hormone Replacement for Premature Ovarian Insufficiency Phase 3